"NGLT-2 buyurishda kardioprotektiv yondashuvlar"
Annotatsiya
Maqsad. Ushbu sharh NGLT-2 ingibitorlarining yurak-qon tomir tizimiga foydalarini, xususan, 2-tur diabet va yurak yetishmovchiligi kabi komorbid kasalliklarga ega bemorlarda yurak salomatligiga ta'sirini o‘rganadi. Asosiy maqsad – ushbu dori vositalarining yurak-qon tomir natijalarini yaxshilashdagi mexanizmlari va samaradorligini baholash.
Usullar. Tegishli ilmiy adabiyotlar bo‘yicha batafsil tahlil o‘tkazildi. Bu tahlil NGLT-2 ingibitorlarining yurak yetishmovchiligi, diabet va u bilan bog‘liq yurak-qon tomir voqealariga ta'sirini o‘rganish uchun klinik tadqiqotlar va meta-tahlillarni o‘z ichiga olgan so‘nggi tadqiqotlarga qaratildi. Tadqiqot ushbu dorilarni yurak-qon tomir kasalliklarini davolashda qo‘llashga oid turli yondashuvlarni tahlil qiladi.
Asosiy mazmun va natijalar. NGLT-2 ingibitorlari yurak-qon tomir tizimi voqealari, jumladan, yurak yetishmovchiligi sababli shifoxonaga yotqizish va o‘lim xavfini sezilarli darajada kamaytirishi aniqlangan. Ularning ta'sir mexanizmlari qondagi glyukoza darajasini yaxshilash, buyrak yukini kamaytirish va endoteliy disfunksiyasini kamaytirishni o‘z ichiga oladi. Tadqiqot ushbu mexanizmlar va yurak yetishmovchiligi hamda 2-tur diabet bilan og‘rigan bemorlarni davolashdagi klinik foydalarini ta'kidlaydi.
Xulosa. NGLT-2 ingibitorlari 2-tur diabet va yurak yetishmovchiligi bilan og‘rigan bemorlarda yurak salomatligini yaxshilash uchun qimmatli davolash usuli hisoblanadi. Ularning qo‘llanilishini optimallashtirish va asosiy mexanizmlarini to‘liq tushunish uchun qo‘shimcha tadqiqotlar talab etiladi.
Mualliflar haqida
Adabiyotlar ro'yxati
Peripech N.B., Mikhaylova I.E., Sodium-glucose cotransporter 2 inhibitors: A successful pursuit of two hares, Russian Cardiology Journal, 2021, S2, 54–62, 10.15829/1560-4071-2021-4534.
Khalimov Y.Sh., Agafonov P.V., Kuzmich V.G., The role and place of dapagliflozin in the management of type 2 diabetes mellitus: From theory to practice, Medical Council, 2017, 3, 22–30, 10.21518/2079-701X- 2017-3-22-30.
Petunina N.A., The modern sodium-glucose cotransporter 2 inhibitor – ertugliflozin, Medical Council, 2023, 17, 06, 234–240, 10.21518/ms2022-032.
Galiero R., Caturano A., Vetrano E., Precision medicine in type 2 diabetes mellitus: Utility and limitations, Diabetes Metab Syndr Obes, 2023, 16, 3669–3689, 10.2147/DMSO.S390752.
Jensen J., Omar M., Kistorp C., Empagliflozin in heart failure patients with reduced ejection fraction: A randomized clinical trial (Empire HF), Trials, 2019, 20, 01, 374, 10.1186/s13063-019-3474-5.
Chwal B.C., Dos Reis R.C. P., Schmidt M.I., Achievement of treatment goals and mortality in individuals with diabetes: The ELSA-Brasil study, J Clin Med, 2023, 12, 024, 7663, 10.3390/jcm12247663.
McGuire D.K., Shih W.J., Cosentino F., Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes: A meta-analysis, JAMA Cardiol, 2021, 6, 02, 148–158, 10.1001/jamacardio.2020.4511.
Chen J.Y., Pan H.C., Shiao C.C., Wu V.C., Impact of SGLT2 inhibitors on patient outcomes: A network meta-analysis, Cardiovasc Diabetol, 2023, 22, 01, 290, 10.1186/s12933-023-02035-8.
Rawshani A., Rawshani A., Franze´n S., Risk factors, mortality, and cardiovascular outcomes in patients with type 2 diabetes, N Engl J Med, 2018, 379, 07, 633–644, 10.1056/NEJMoa1800256.
Petrie M.C., Verma S., Docherty K.F., Effect of dapagliflozin on worsening heart failure and cardiovascular death in patients with heart failure with and without diabetes, JAMA, 2020, 323, 014, 1353–1368, 10.1001/jama.2020.1906.
Vaduganathan M., Docherty K.F., Solomon S.D., NGLT-2 inhibitors in patients with heart failure: A comprehensive meta-analysis of five randomized controlled trials, Lancet, 2022, 400, 010354, 757–767, 10.1016/S0140-6736(22)01429-5.
Talha K.M., Butler J., Greene S.J., Fonarow G.C., Population-level implications of sodium-glucose cotransporter-2 inhibitors for heart failure with preserved ejection fraction in the US, JAMA Cardiol, 2023, 8, 01, 66–73, 10.1001/jamacardio.2022.4348.
Neal B., Perkovic V., Mahaffey K.W., Canagliflozin and cardiovascular and renal events in type 2 diabetes, N Engl J Med, 2017, 377, 07, 644–657, 10.1056/NEJMc1712572.
Sano M., Takei M., Shiraishi Y., Increased hematocrit during sodium-glucose cotransporter 2 inhibitor therapy indicates recovery of tubulointerstitial function in diabetic kidneys, J Clin Med Res, 2016, 8, 012, 844–847, 10.14740/jocmr2760w.
Lam C.S., Chandramouli C., Ahooja V., NGLT-2 inhibitors in heart failure: Current management, unmet needs, and therapeutic prospects, J Am Heart Assoc, 2019, 8, 020, e013389, 10.1161/JAHA.119.013389.
Zinman B., Wanner C., Lachin J.M., Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes, N Engl J Med, 2015, 373, 022, 2117–2128, 10.1056/NEJMoa1504720.
Sakai T., Miura S., Effects of sodium-glucose cotransporter 2 inhibitor on vascular endothelial and diastolic function in heart failure with preserved ejection fraction: Novel prospective cohort study, Circ Rep, 2019, 1, 07, 286–295, 10.1253/circrep.CR-19-0018.
Levine M.J., Empagliflozin for type 2 diabetes mellitus: An overview of phase 3 clinical trials, Curr Diabetes Rev, 2017, 13, 04, 405–423, 10.2174/1573399812666160613113556.
McGuire D.K., Shih W.J., Cosentino F., Charbonnel B., Cherney D.Z. I., Dagogo-Jack S., Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes: A meta-analysis, JAMA Cardiol, 2021, 6, 148–158, 10.1001/jamacardio.2020.4511.
Ushbu asar saytida mavjud litsenziyalar Creative Commons «Attribution-NonCommercial-ShareAlike» («Atribut - notijorat maqsadlarda foydalanish - bir xil shartlar») 4.0 Всемирная.